Literature DB >> 25022514

Targeted injection of a biocomposite material alters macrophage and fibroblast phenotype and function following myocardial infarction: relation to left ventricular remodeling.

Jeremy R McGarvey1, Sara Pettaway1, James A Shuman1, Craig P Novack1, Kia N Zellars1, Parker D Freels1, Randall L Echols1, Jason A Burdick1, Joseph H Gorman1, Robert C Gorman1, Francis G Spinale2.   

Abstract

A treatment target for progressive left ventricular (LV) remodeling prevention following myocardial infarction (MI) is to affect structural changes directly within the MI region. One approach is through targeted injection of biocomposite materials, such as calcium hydroxyapatite microspheres (CHAM), into the MI region. In this study, the effects of CHAM injections upon key cell types responsible for the MI remodeling process, the macrophage and fibroblast, were examined. MI was induced in adult pigs before randomization to CHAM injections (20 targeted 0.1-ml injections within MI region) or saline. At 7 or 21 days post-MI (n = 6/time point per group), cardiac magnetic resonance imaging was performed, followed by macrophage and fibroblast isolation. Isolated macrophage profiles for monocyte chemotactic macrophage inflammatory protein-1 as measured by real-time polymerase chain reaction increased at 7 days post-MI in the CHAM group compared with MI only (16.3 ± 6.6 versus 1.7 ± 0.6 cycle times values, P < 0.05), and were similar by 21 days post-MI. Temporal changes in fibroblast function and smooth muscle actin (SMA) expression relative to referent control (n = 5) occurred with MI. CHAM induced increases in fibroblast proliferation, migration, and SMA expression-indicative of fibroblast transformation. By 21 days, CHAM reduced LV dilation (diastolic volume: 75 ± 2 versus 97 ± 4 ml) and increased function (ejection fraction: 48 ± 2% versus 38 ± 2%) compared with MI only (both P < 0.05). This study identified that effects on macrophage and fibroblast differentiation occurred with injection of biocomposite material within the MI, which translated into reduced adverse LV remodeling. These unique findings demonstrate that biomaterial injections impart biologic effects upon the MI remodeling process over any biophysical effects. U.S. Government work not protected by U.S. copyright.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25022514      PMCID: PMC4152878          DOI: 10.1124/jpet.114.215798

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  44 in total

Review 1.  Healing after myocardial infarction.

Authors:  Georg Ertl; Stefan Frantz
Journal:  Cardiovasc Res       Date:  2005-04-01       Impact factor: 10.787

2.  User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability.

Authors:  Paul A Yushkevich; Joseph Piven; Heather Cody Hazlett; Rachel Gimpel Smith; Sean Ho; James C Gee; Guido Gerig
Journal:  Neuroimage       Date:  2006-03-20       Impact factor: 6.556

3.  CCL2/Monocyte Chemoattractant Protein-1 regulates inflammatory responses critical to healing myocardial infarcts.

Authors:  Oliver Dewald; Pawel Zymek; Kim Winkelmann; Anna Koerting; Guofeng Ren; Tareq Abou-Khamis; Lloyd H Michael; Barrett J Rollins; Mark L Entman; Nikolaos G Frangogiannis
Journal:  Circ Res       Date:  2005-03-17       Impact factor: 17.367

4.  Age-dependent changes in myocardial matrix metalloproteinase/tissue inhibitor of metalloproteinase profiles and fibroblast function.

Authors:  Merry L Lindsey; Danielle K Goshorn; Christina E Squires; G Patricia Escobar; Jennifer W Hendrick; Joseph T Mingoia; Sarah E Sweterlitsch; Francis G Spinale
Journal:  Cardiovasc Res       Date:  2004-12-13       Impact factor: 10.787

5.  Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling.

Authors:  Carson S Webb; David D Bonnema; S Hinan Ahmed; Amy H Leonardi; Catherine D McClure; Leslie L Clark; Robert E Stroud; William C Corn; Laura Finklea; Michael R Zile; Francis G Spinale
Journal:  Circulation       Date:  2006-08-21       Impact factor: 29.690

6.  Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion.

Authors:  M Lindsey; K Wedin; M D Brown; C Keller; A J Evans; J Smolen; A R Burns; R D Rossen; L Michael; M Entman
Journal:  Circulation       Date:  2001-05-01       Impact factor: 29.690

Review 7.  Calcium hydroxylapatite: Radiesse.

Authors:  Min S Ahn
Journal:  Facial Plast Surg Clin North Am       Date:  2007-02       Impact factor: 1.918

8.  Local hydrogel release of recombinant TIMP-3 attenuates adverse left ventricular remodeling after experimental myocardial infarction.

Authors:  Shaina R Eckhouse; Brendan P Purcell; Jeremy R McGarvey; David Lobb; Christina B Logdon; Heather Doviak; Jason W O'Neill; James A Shuman; Craig P Novack; Kia N Zellars; Sara Pettaway; Roy A Black; Aarif Khakoo; Taeweon Lee; Rupak Mukherjee; Joseph H Gorman; Robert C Gorman; Jason A Burdick; Francis G Spinale
Journal:  Sci Transl Med       Date:  2014-02-12       Impact factor: 17.956

9.  Matrix metalloproteinase abundance in human myocardial fibroblasts: effects of sustained pharmacologic matrix metalloproteinase inhibition.

Authors:  R English Chapman; Amelia A Scott; Anne M Deschamps; Abigail S Lowry; Robert E Stroud; John S Ikonomidis; Francis G Spinale
Journal:  J Mol Cell Cardiol       Date:  2003-05       Impact factor: 5.000

10.  Effect of monopolar radiofrequency treatment over soft-tissue fillers in an animal model: part 2.

Authors:  Peter R Shumaker; Laura J England; Jeffrey S Dover; E Victor Ross; Robert Harford; Damian Derienzo; Melissa Bogle; Nathan Uebelhoer; Mark Jacoby; Karl Pope
Journal:  Lasers Surg Med       Date:  2006-03       Impact factor: 4.025

View more
  14 in total

1.  Sustained Release of a Peptide-Based Matrix Metalloproteinase-2 Inhibitor to Attenuate Adverse Cardiac Remodeling and Improve Cardiac Function Following Myocardial Infarction.

Authors:  Zhaobo Fan; Minghuan Fu; Zhaobin Xu; Bo Zhang; Zhihong Li; Haichang Li; Xinyu Zhou; Xuanyou Liu; Yunyan Duan; Pei-Hui Lin; Pu Duann; Xiaoyun Xie; Jianjie Ma; Zhenguo Liu; Jianjun Guan
Journal:  Biomacromolecules       Date:  2017-08-07       Impact factor: 6.988

Review 2.  Developing injectable nanomaterials to repair the heart.

Authors:  Mary M Nguyen; Nathan C Gianneschi; Karen L Christman
Journal:  Curr Opin Biotechnol       Date:  2015-04-11       Impact factor: 9.740

3.  Injectable microsphere gel progressively improves global ventricular function, regional contractile strain, and mitral regurgitation after myocardial infarction.

Authors:  Jeremy R McGarvey; Norihiro Kondo; Walter R T Witschey; Manabu Takebe; Chikashi Aoki; Jason A Burdick; Francis G Spinale; Joseph H Gorman; James J Pilla; Robert C Gorman
Journal:  Ann Thorac Surg       Date:  2014-12-15       Impact factor: 4.330

Review 4.  Ventricular wall biomaterial injection therapy after myocardial infarction: Advances in material design, mechanistic insight and early clinical experiences.

Authors:  Yang Zhu; Yasumoto Matsumura; William R Wagner
Journal:  Biomaterials       Date:  2017-03-01       Impact factor: 12.479

5.  Modulating In Vivo Degradation Rate of Injectable Extracellular Matrix Hydrogels.

Authors:  Jean W Wassenaar; Rebecca L Braden; Kent G Osborn; Karen L Christman
Journal:  J Mater Chem B       Date:  2016-03-28       Impact factor: 6.331

6.  UM206, a selective Frizzled antagonist, attenuates adverse remodeling after myocardial infarction in swine.

Authors:  André Uitterdijk; Kevin C M Hermans; Daphne P M de Wijs-Meijler; Evangelos P Daskalopoulos; Irwin K Reiss; Dirk J Duncker; W Matthijs Blankesteijn; Daphne Merkus
Journal:  Lab Invest       Date:  2015-12-14       Impact factor: 5.662

7.  Injectable Supramolecular Hydrogel/Microgel Composites for Therapeutic Delivery.

Authors:  Minna H Chen; Jennifer J Chung; Joshua E Mealy; Samir Zaman; Elizabeth C Li; Maria F Arisi; Pavan Atluri; Jason A Burdick
Journal:  Macromol Biosci       Date:  2018-09-27       Impact factor: 4.979

8.  NIPAM-based Microgel Microenvironment Regulates the Therapeutic Function of Cardiac Stromal Cells.

Authors:  Xiaolin Cui; Junnan Tang; Yusak Hartanto; Jiabin Zhang; Jingxiu Bi; Sheng Dai; Shi Zhang Qiao; Ke Cheng; Hu Zhang
Journal:  ACS Appl Mater Interfaces       Date:  2018-10-29       Impact factor: 9.229

9.  CircUbe3a from M2 macrophage-derived small extracellular vesicles mediates myocardial fibrosis after acute myocardial infarction.

Authors:  Yan Wang; Chaofu Li; Ranzun Zhao; Zhimei Qiu; Changyin Shen; Zhenglong Wang; Weiwei Liu; Wei Zhang; Junbo Ge; Bei Shi
Journal:  Theranostics       Date:  2021-04-15       Impact factor: 11.556

10.  Fibroblast growth factor-2 regulates human cardiac myofibroblast-mediated extracellular matrix remodeling.

Authors:  Daniyil A Svystonyuk; Janet M C Ngu; Holly E M Mewhort; Brodie D Lipon; Guoqi Teng; David G Guzzardi; Getanshu Malik; Darrell D Belke; Paul W M Fedak
Journal:  J Transl Med       Date:  2015-05-07       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.